Efficacy of pregabalin in depressive symptoms associated with generalized anxiety disorder: a pooled analysis of 6 studies

Stein, Dan J., Baldwin, David S., Baldinetti, Francesca and Mandel, Francine (2008) Efficacy of pregabalin in depressive symptoms associated with generalized anxiety disorder: a pooled analysis of 6 studies. European Neuropsychopharmacology, 18, (6), 422-430. (doi:10.1016/j.euroneuro.2008.01.004).


Full text not available from this repository.


Epidemiological evidence supports comorbidity of generalized anxiety disorder (GAD) and major depressive disorder (MDD) or dysthymia, and its association with significant disability. As pregabatin, a new alpha(2)-delta anxiolytic treatment for GAD, unlike most other licensed treatments for GAD has not undergone investigation in patients with MDD, we examined its efficacy in depressive symptoms associated with GAD, through a post-hoc analysis of the existing clinical trial database. The results provide consistent evidence that in patients with GAD pregabalin reduced associated symptoms of depression. This was seen in the 150 mg/day, 300-450 mg/day and 600 mg/day dosing groups. Even in subjects with more prominent depressive symptoms, pregabalin remained effective for both sub-syndromal depression and GAD symptoms, with pregabatin 300-450 mg/day demonstrating the most beneficial response. In conclusion, pregabalin, an alternative treatment option for GAD with a novel mechanism of action, also demonstrated efficacy in treating depressive symptoms typically encountered in GAD patients.

Item Type: Article
Digital Object Identifier (DOI): doi:10.1016/j.euroneuro.2008.01.004
ISSNs: 0924-977X (print)
Related URLs:
Keywords: efficacy, generalized anxiety disorder, major depression, diabetic peripheral neuropathy, double-blind, postherpetic neuralgia, rat neocortical slices, gad, protein-kinase-c,comorbid depressive symptoms, pregabalin, dsm-iv, primary-care, major depressive disorder, venlafaxine extended-release, placebo-controlled trial
Subjects: R Medicine > RC Internal medicine > RC0321 Neuroscience. Biological psychiatry. Neuropsychiatry
R Medicine > RS Pharmacy and materia medica
R Medicine > RM Therapeutics. Pharmacology
Divisions : University Structure - Pre August 2011 > School of Medicine > Clinical Neurosciences
ePrint ID: 62612
Accepted Date and Publication Date:
June 2008Published
Date Deposited: 04 Nov 2008
Last Modified: 31 Mar 2016 12:46
URI: http://eprints.soton.ac.uk/id/eprint/62612

Actions (login required)

View Item View Item